Merck & Co., Inc. — Director's Dealing 2022

Nov 7, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Merck & Co., Inc. (MRK)
CIK: 0000310158
Period of Report: 2022-11-03

Reporting Person: FRAZIER KENNETH C (Director, Executive Chair)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2022-11-03	Common Stock	M	235000	—	Acquired	935653.063	Direct
2022-11-03	Common Stock	S	214617	$98.6785	Disposed	721036.063	Direct
2022-11-03	Common Stock	S	20383	$99.0926	Disposed	700653.063	Direct
2022-11-04	Common Stock	M	235000	—	Acquired	935653.063	Direct
2022-11-04	Common Stock	S	200190	$98.5326	Disposed	735463.063	Direct
2022-11-04	Common Stock	S	34810	$99.0804	Disposed	700653.063	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2022-11-03	Stock Option (Right to Buy)	$53.06	M	235000	Disposed	2026-05-09	Common Stock (235000)	Direct
2022-11-04	Stock Option (Right to Buy)	$53.06	M	235000	Disposed	2026-05-09	Common Stock (235000)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock - 401(k) Plan	4481.1286	Indirect

Footnotes

F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $98.0500 to $99.0500, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote.

F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $99.0600 to $99.2000, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote.

F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $97.9700 to $98.9700, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote.

F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $98.9800 to $99.2800, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote.

F5: Holdings include shares acquired in dividend reinvestment transactions.

F6: Includes shares acquired and dividends earned through October 7, 2022 in the Merck U.S. Savings Plan, a 401(k) plan.

F7: The option became exercisable in equal installments on 5/10/2017, 5/10/2018 and 5/10/2019.